Here and Now: Biosimilars for the treatment of IBD

Here and Now: Biosimilars for the treatment of IBD

A satellite symposium held in conjunction with the 2017 Advances in Inflammatory Bowel Diseases: Multidisciplinary Approaches to IBD Patient-Centered Care conference.

Friday, November 10, 2017
Northern Hemisphere Ballroom, A-B
12:45 pm – 1:45 pm
Support by: Samsung Bioepis

REGISTER NOW

 

Chair

David T. Rubin, MD, FACG
University of Chicago Medicine
Chicago, Illinois

Faculty

Suchira Ghosh, JD
Axinn, Veltrop & Harkrider LLP
New York, New York

Stephen B. Hanauer, MD, FACG
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Agenda

12:45 pm

Welcome and pre-activity survey
David T. Rubin, MD, FACG

12:50 pm

Unmet needs and updated goals of management of IBD
David T. Rubin, MD, FACG

1:00 pm

Regulatory pathway for biosimilars
Suchira Ghosh, JD

1:15 pm

Status of biosimilars in US & Experience from Asia & Europe
Stephen B. Hanauer, MD, FACG

1:30 pm

Clinical scenarios where biosimilars may or may not be used
David T. Rubin, MD, FACG

1:40 pm

Questions & ARS post-test questions
David T. Rubin, MD, FACG

1:45 pm

Adjourn

Accreditation

ACCMEImedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Who Should Attend

This live activity is designed to meet the educational needs of Physicians, surgeons, nurse practitioners, pharmacists, physician assistants, nurses, and other healthcare professionals who are involved and/or interested in the treatment of patients with IBD.

Learning Objectives

After successful completion of the recommended education, participants should be able to:

  • Discuss the rationale for use of biosimilars and their potential role in IBD
  • Identify new and emerging biosimilar agents for the treatment of IBD
  • Characterize the inherent differences between biosimilars and their reference biologics based on their manufacturing processes
  • Evaluate the FDA regulatory pathway for approval of biosimilars with that of their reference biologics
  • Contrast the efficacy and safety/tolerability profiles of IBD biosimilars with those of their reference biologics
Support

The following company has provided an educational grant in support of this symposium: Samsung Bioepis.

Registration

Registration Fees
Registration is complimentary to those registered to attend the Advances in Inflammatory Bowel Diseases: Multidisciplinary Approaches to IBD Patient-Centered Care conference.

Available seating will be based on room capacity. Seating is limited and pre-registration is for planning purposes only and does not guarantee admission, as the room may be overbooked. Early arrival is recommended and seating will be first-come first-serve until capacity is met.

Location

Conference Location and Hotel Accommodations
Walt Disney World Dolphin Hotel
1500 Epcot Resorts Boulevard
Lake Buena Vista, Florida 32838
Tel.: +1 (407) 934 4000
http://www.swandolphin.com/home.html

The Registration and Information Desk at the Norther Hemisphere Foyer will be staffed:
Friday, November 10, 2017…………………………12:30 pm – 1:45 pm

Symposium Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
FacebookTwitterLinkedInEmail